INmune Bio Inc

INmune Bio Inc has a market capitalization of $44.66 million and a price-to-book ratio of 1.54, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by $26.00 million in cash and equivalents, which is significantly higher than its total liabilities of $17.81 million, resulting in a current ratio of 1.71. This suggests that the company has sufficient short-term liquidity to cover its obligations.

The company's profitability is currently negative, with a net income of -$11.03 million and an operating income of -$11.02 million. Its return on equity is -37.99%, and its return on assets is -23.54%, both of which are well below the typical thresholds for profitability in the biotechnology industry. The company's debt-to-equity ratio of 0.26 indicates a relatively low level of leverage, which is common for early-stage biotechnology firms.

INmune Bio Inc's revenue is not segmented by geographic region or product line in the available data, but the company's operations are likely concentrated in the United States, as is typical for many biotechnology firms. The company's revenue of $14.00 million is modest, and there is no indication of significant geographic diversification.

The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's operating cash flow is negative at -$7.48 million, which is a concern for its ability to fund operations without external financing. The company's reliance on external financing is further indicated by its high price-to-revenue ratio of 1,865.45, which is typical for early-stage biotechnology companies with limited revenue and high R&D expenses.

The company's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, as there are no significant dilution sources identified in the available data. The company's financial position is supported by its strong cash reserves, which provide a buffer against short-term financial risks.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's analyst estimates suggest a wide range of price targets, with a mean of $7.00 and a median of $7.50, indicating a generally positive outlook among analysts. The company's mean recommendation is 2.00, which is a "Buy" rating, and there are four "Buy" ratings and no "Strong Buy" or "Hold" ratings.

Analysts project 238% upside to a mean price target of $7.00, signaling strong institutional confidence in future value.

The company maintains a low leverage band with a debt-to-equity ratio of 0.38, reducing financial distress risk.

A current ratio of 3.55 indicates strong short-term liquidity, providing a buffer against immediate operational cash needs.

Long-term debt decreased significantly from $14.7 million in 2023 to zero in 2025, improving the balance sheet structure.

Revenue increased 257% year-over-year to $50,000 in FY2026, suggesting potential early-stage commercial traction or milestone recognition.

Net income deteriorated to -$45.9 million in FY2026, reflecting a 9.2% worsening trend from the previous fiscal year.

Operating margins of -787% place the company in the bottom quartile of its biotechnology cohort, indicating severe inefficiency.

The company carries a high credit risk flag, suggesting significant challenges in meeting long-term financial obligations.

Revenue $0.00; Operating income +42,2% YoY.

• ▍Revenue $0.00
• ▍Operating income +42,2% YoY
• ▍Net income +42,9% YoY

Revenue $0.00; Operating income +39,5% YoY.

• ▍Revenue $0.00
• ▍Operating income +39,5% YoY
• ▍Net income +46,5% YoY

Revenue $0.00; Operating income −149,1% YoY.

• ▍Revenue $0.00
• ▍Operating income −149,1% YoY
• ▍Net income −150,9% YoY

Revenue $50.0k, +257,1% YoY; Operating income +10,1% YoY.

• ▍Revenue $50.0k, +257,1% YoY
• ▍Operating income +10,1% YoY
• ▍Net income +11,7% YoY
• ▍Net margin -19478.0%

Revenue $0.00; Operating income -$9.5M.

• ▍Revenue $0.00
• ▍Operating income -$9.5M

Revenue $0.00; Operating income -$12.3M.

• ▍Revenue $0.00
• ▍Operating income -$12.3M

Revenue $0.00; Operating income -$9.9M.

• ▍Revenue $0.00
• ▍Operating income -$9.9M

Revenue $14.0k; Operating income -$11.0M.

• ▍Revenue $14.0k
• ▍Operating income -$11.0M
• ▍Net margin -78750.0%

Revenue $50.0k, +257,1% YoY; Operating income −11,1% YoY.

• ▍Revenue $50.0k, +257,1% YoY
• ▍Operating income −11,1% YoY
• ▍Net income −9,2% YoY
• ▍Net margin -91866.0%

Revenue $14.0k, −91,0% YoY; Operating income −43,4% YoY.

• ▍Revenue $14.0k, −91,0% YoY
• ▍Operating income −43,4% YoY
• ▍Net income −40,2% YoY
• ▍Net margin -300585.7%

Revenue $155.0k, −58,6% YoY; Operating income −14,6% YoY.

• ▍Revenue $155.0k, −58,6% YoY
• ▍Operating income −14,6% YoY
• ▍Net income −9,9% YoY
• ▍Net margin -19360.0%

Revenue $374.0k, +106,6% YoY; Operating income +11,0% YoY.

• ▍Revenue $374.0k, +106,6% YoY
• ▍Operating income +11,0% YoY
• ▍Net income +10,0% YoY
• ▍Net margin -7299.2%